Table 1 Clinical characteristics of individuals
From: Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy
| Â | Discovery and training set | Large-scale validation set | ||
|---|---|---|---|---|
| Â | Epilepsy | Control | Epilepsy | Control |
No. | 30 | 30 | 117 | 112 |
Age, mean ± SD (y) | 26.4 ± 11.5 | 29.2 ± 5.6 | 29.8 ± 10.3 | 31.8 ± 9.0 |
Female:Male | 15:15 | 15:15 | 57:60 | 59:53 |
BMI, mean ± SD (kg/m2) | 22.5 ± 4.2 | 23.5 ± 3.4 | 23.0 ± 4.2 | 23.6 ± 3.3 |
Duration, median (range) (y) | 4.5(1–32) | NA | 6(1–39) | NA |
Seizure frequency, median(range) (/6 months) | 20(3–118) | NA | 12(1–167) | NA |
Aetiology | ||||
Symptomatic | 8(26.7%) | NA | 35(29.9%) | NA |
Idiopathic | 5(16.7%) | NA | 19(16.2%) | NA |
Crytogenic | 17(56.7%) | NA | 63(53.8%) | NA |
Seizure type | ||||
Partial | 12(40.0%) | NA | 39(33.3%) | NA |
Generalized | 18(60.0%) | NA | 78(66.7%) | NA |
AED therapy at the last clinic visit | ||||
Monotherapy | 13(43.3%) | NA | 46(39.3%) | NA |
Polytherapy | 17(56.7%) | NA | 71(60.7%) | NA |
